Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Pharmaust Limited ( (AU:NUZ) ) is now available.
Neurizon Therapeutics has secured registered trademark protection for the NEURIZON brand across its key global commercial markets, including the United States, European Union, United Kingdom, Australia and Japan, covering pharmaceutical research and development, clinical trial services and neurological therapeutics. The completion of this global trademark portfolio, particularly the US registration in Neurizon’s primary long-term commercialisation market, strengthens the company’s intellectual property framework alongside patent protection for lead asset NUZ-001, supports consistent global brand deployment and enhances strategic flexibility for future partnerships or independent commercialisation as it advances towards later-stage clinical development.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Its lead drug candidate, NUZ-001, is being developed for amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease, with a strategy to accelerate patient access to effective ALS therapies and explore broader neurodegenerative applications through international collaborations and clinical programs.
YTD Price Performance: -3.53%
Average Trading Volume: 530,047
Technical Sentiment Signal: Sell
Current Market Cap: A$68.01M
For an in-depth examination of NUZ stock, go to TipRanks’ Overview page.